Austin, Texas, United States
A strategic finance executive with over 20 years of experience leading financial operations in multiple industries, with a heavy focus in the biotechnology and pharmaceutical industry. In-depth knowledge of board reporting, capital raises, public financial reporting, corporate finance and governance. Specialties: • Board of Directors Reporting • Capital Raises and Allocation • Investor Relations • Licensing • Financial & SEC Reporting • Sarbanes-Oxley Compliance • IPO Readiness • Financial Planning & Analysis • Corporate Governance • Treasury and Debt Management • International Business
- Led the finance and public reporting process for the second largest life science collaboration of 2022 ($6.3B), with $150M upfront, up to $6B in regulatory and commercial milestones, and $100M in equity financing. - Transformed a finance department at a high-growth public company into a controlled, efficient, and scalable operation. Market capitalization had grown from $300M to $3B in less than 2 years beforehand.
- Successfully led and built the finance operations from a Series A start-up through IPO and into a well-run public company. - Led and managed the underwriter and investor diligence, in addition to the SEC filings for over 5 public offerings, raising over $400M, through an IPO, follow-ons, and ATM transactions. - Developed the commercial launch readiness plan to build the finance and accounting infrastructure for the company’s first product launch.